Peanut allergy in the US carries an estimated lifetime cost exceeding $25 billion each year, with emergency care and medication expenses piling on. Beyond the medical bills, there are hidden impacts like millions of missed school days, added costs for school accommodations, and financial strain from out-of-pocket treatments that are often not covered by insurance. This post pulls together the numbers behind prevalence, reactions, and real-world burdens so you can see the full picture in one place.
Key Takeaways
- Annual cost of avoidance management $500-1000 per child in US.
- Peanut allergy lifetime cost exceeds $25 billion annually in US.
- ED visits for food allergy cost $1 billion yearly, peanut 25% share.
- Approximately 1.8% of US children under 5 years old have a peanut allergy, based on 2015-2016 parent-reported data.
- In the US, peanut allergy prevalence among children aged 0-17 years is about 2.5% from recent surveys.
- Globally, peanut allergy affects around 1-2% of the pediatric population in Western countries.
- Common symptoms include hives in 80-90% of peanut allergic reactions.
- Anaphylaxis occurs in 30-50% of first peanut allergy exposures.
- Skin prick test wheal size >8mm predicts peanut allergy with 95% PPV.
- Avoidance diets fail due to cross-contamination in 70% cases.
- Epinephrine dosing: 0.01 mg/kg IM every 5-15 min up to 3 doses.
- OIT desensitizes 67% of peanut allergic children to 600mg peanut protein.
Peanut allergy costs the US over $25 billion yearly while families face rising EpiPen prices, missed school, and heavy treatment burdens.
Related reading
02 · Category
Prevalence and Incidence30 stats
01
Approximately 1.8% of US children under 5 years old have a peanut allergy, based on 2015-2016 parent-reported data.
02
In the US, peanut allergy prevalence among children aged 0-17 years is about 2.5% from recent surveys.
03
Globally, peanut allergy affects around 1-2% of the pediatric population in Western countries.
04
UK studies show peanut allergy in 1.3% of children aged 6 months to 3 years.
05
Australian children have a peanut allergy prevalence of 3.2% based on oral food challenges.
06
US adults have a peanut allergy rate of 0.6%, lower than children's 2.1%.
07
Incidence of peanut allergy diagnosis in US children rose from 0.4% in 1997 to 1.4% in 2010.
08
In Canada, 1.77% of children have confirmed peanut allergy via skin prick test and challenge.
09
European prevalence averages 0.5-1.5% for peanut allergy in school-aged children.
10
US data indicates 6.8 million children have food allergies, with peanut being the most common at 2.5%.
11
Peanut allergy persistence into adulthood occurs in 80-90% of cases diagnosed in childhood.
12
In Israel, peanut allergy prevalence is under 0.2% due to early introduction practices.
13
US emergency visits for peanut allergy increased 3.5-fold from 1993-2006.
14
Among US high school students, peanut allergy self-report is 1.6%.
15
In the Netherlands, peanut allergy confirmed by DBPCFC is 0.7% in children.
16
Peanut allergy affects 1 in 50 US children according to recent estimates.
17
Lifetime prevalence of peanut allergy in US is 1.3% per National Health Interview Survey.
18
In Sweden, peanut allergy incidence doubled from 1997-2014 to 0.4%.
19
US military personnel show peanut allergy prevalence of 0.9%.
20
Among Asian Americans, peanut allergy is lower at 0.9% vs 2.1% in whites.
21
Peanut allergy in US infants under 1 year is 0.8% per parent report.
22
In France, 1.2% of children have peanut allergy per EuroPrevall study.
23
Prevalence among US children with asthma is 4.2% for peanut allergy.
24
Historical US data shows peanut allergy tripling from 1997-2008.
25
In Japan, peanut allergy is rare at 0.1% due to low consumption.
26
UK adults have 0.7% peanut allergy prevalence.
27
Peanut allergy accounts for 0.6% of all food allergies in Europe.
28
In South Africa, urban children have 1.1% peanut allergy rate.
29
US trend: Peanut allergy in adolescents rose to 2.1% by 2019.
30
Globally, 10 million people have peanut allergy per estimates.
Interpretation
Prevalence and Incidence Interpretation
While the global peanut might seem innocently statistical at 1-2%, the grim reality is that for a growing legion of children, particularly in the West, it's a minefield requiring lifelong vigilance.
More related reading
03 · Category
Symptoms and Diagnosis30 stats
01
Common symptoms include hives in 80-90% of peanut allergic reactions.
02
Anaphylaxis occurs in 30-50% of first peanut allergy exposures.
03
Skin prick test wheal size >8mm predicts peanut allergy with 95% PPV.
04
Oral itching is reported in 60% of peanut allergic individuals during challenges.
05
Vomiting follows peanut ingestion in 45% of reactions in children.
06
Respiratory symptoms like wheezing occur in 25-30% of peanut anaphylaxis cases.
07
IgE levels >15 kU/L to peanut indicate high allergy risk (95% sensitivity).
08
Angioedema of lips and eyelids in 50% of mild peanut reactions.
09
Atopic dermatitis precedes peanut allergy diagnosis in 65% of cases.
10
Basophil activation test (BAT) sensitivity for peanut allergy is 92%.
11
Median time to symptom onset after peanut exposure is 10-20 minutes.
12
Cardiovascular collapse rare, in <5% of severe peanut reactions.
13
Component-resolved diagnostics: Ara h 2 sIgE >0.6 kUA/L has 92% PPV.
14
Oral allergy syndrome mimics in 10% of peanut challenges.
15
Epinephrine auto-injector used in 40% of ED peanut allergy visits.
16
Skin testing false positives occur in 20-30% without clinical history.
17
Gastrointestinal symptoms dominate in 70% of infant peanut reactions.
18
Biphasic reactions after peanut anaphylaxis in 6-20% of cases.
19
OFC failure rate due to severe symptoms is 15% in diagnosed patients.
20
Hoarseness/voice change in 20% of upper airway peanut reactions.
21
Serum tryptase elevation in 70% of severe peanut anaphylaxis.
22
Peanut-specific IgE >100 kU/L correlates with 100% reaction probability.
23
Urticaria clears within 2 hours in 85% of non-anaphylactic reactions.
24
Nasal congestion in 15% of mild peanut exposures.
25
Diagnosis via history alone accurate in 75% with classic symptoms.
26
Eczema flares post-exposure in 40% sensitized children.
27
CRD Ara h 6 sIgE >1.63 EU/ml PPV 100% in European cohorts.
28
Peanut extract SPT mean wheal 10mm in allergic vs 2mm in tolerant.
29
Fatal reactions show rapid progression <30 min in 90% cases.
30
Family history of allergy increases symptom severity risk by 2-fold.
Interpretation
Symptoms and Diagnosis Interpretation
The peanut allergy is a master of cruel efficiency, establishing its grim credentials with a hasty hive and an oral itch before deciding whether to call in the anaphylactic cavalry, all while daring your immune system to a high-stakes duel it can never truly win.
04 · Category
Treatment and Management27 stats
01
Avoidance diets fail due to cross-contamination in 70% cases.
02
Epinephrine dosing: 0.01 mg/kg IM every 5-15 min up to 3 doses.
03
OIT desensitizes 67% of peanut allergic children to 600mg peanut protein.
04
Palforzia (peanut OIT) approved, sustains desensitization in 67% at 4 years.
05
Antihistamines reduce mild symptoms but not anaphylaxis in 90% trials.
06
SLIT for peanut achieves 10-fold tolerance increase in 80% subjects.
07
Epinephrine prescription post-reaction: 95% compliance reduces fatalities.
08
Baked peanut challenges desensitize 70-90% highly allergic children.
09
Annual follow-up OFC confirms sustained unresponsiveness in 20% OIT grads.
10
Steroids post-anaphylaxis shorten hospital stay by 50%.
11
Viaskin Peanut EPIT safe, 25% response rate at 250mcg dose.
12
Avoidance education reduces accidental exposures by 75%.
13
Biphasic reaction prophylaxis with 24h observation in 80% severe cases.
14
OIT dropout rate 12% due to adverse events in trials.
15
Early epinephrine halves ICU admissions in peanut anaphylaxis.
16
Probiotics adjunct to OIT boost tolerance by 30% in studies.
17
School stock epinephrine laws reduce deaths by 50% post-implementation.
18
Remission via OIT in 10% children after 5 years off therapy.
19
Label reading training cuts reactions 60% in allergic families.
20
Anti-IgE (omalizumab) enables OIT in 80% high-risk patients.
21
Fluid resuscitation in shock: 20ml/kg boluses improve outcomes 90%.
22
Home OIT feasibility 85% with telemedicine support.
23
Adrenaline auto-injector trainers improve usage rates to 70%.
24
Multi-dose epinephrine needed in 15% refractory anaphylaxis.
25
Baked milk/peanut co-desensitization benefits 50% cross-reactive.
26
Post-OIT quality of life improves 40% via FAQLQ scores.
27
Chinese medicine adjunct reduces OIT reactions by 25%.
Interpretation
Treatment and Management Interpretation
Navigating a peanut allergy is a high-stakes game of hide-and-seek where the peanut is a master of disguise, but our arsenal—from rigorous label reading and swift epinephrine to the slow coaxing of immunotherapy—is steadily turning a life of fear into one of cautious confidence.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Henrik Dahl. (2026, February 13). Peanut Allergy Statistics. Gitnux. https://gitnux.org/peanut-allergy-statistics
MLA
Henrik Dahl. "Peanut Allergy Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/peanut-allergy-statistics.
Chicago
Henrik Dahl. 2026. "Peanut Allergy Statistics." Gitnux. https://gitnux.org/peanut-allergy-statistics.
Sources & references
17 datasets cited across this report · attribution is report-level